Answers are grounded in this paper and cite their sources.
OBJECTIVE: To highlight the efficacy of dupilumab in treating chronic otitis media with effusion (glue ear). PATIENTS: Three patients with chronic otitis media with effusion (OME) refractory to medical and surgical treatment were retrospectively identified. All patients had medical history suggestive of the presence of eosinophilic inflammation. INTERVENTIONS: Each patient received a 300-mg injection of dupilumab every 4 weeks for a total of three injections. MAIN OUTCOME MEASURES: Audiometric data, patient-reported incidence of new ear infections, patient-reported symptoms. RESULTS: All patients reported subjective improvement in ear pain, drainage, and hearing loss between 2 weeks and 6 months on dupilumab therapy. In case 1 and case 2, audiograms showed some improvement in hearing loss posttreatment. Case 2 had an unexpected interruption of treatment for 4 weeks and reported return of thick ear drainage and difficulty with hearing. CONCLUSIONS: Dupilumab may be a novel, effective, and nonsurgical treatment option for patients with chronic otitis media with effusion and underlying atopic conditions.
No takes yet. Share an insight, caveat, or question.
Kallenberger et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: